retatrutide triple agonist gip glp-1 glucagon phase 3 2025 First data, a Triumph of Science! First Retatrutide phase 3 data,
Description
The study demonstrates that quantitative target engagement of dual agonists can be assessed by PET.
Thirteen state Medicaid programs are covering GLP-1 drugs for the treatment of obesity this year, down from 16 last year.
Starting July 1, 2026, the Centers for Medicare and Medicaid Services (CMS) will launch a new federal program that gives many Medicare beneficiaries access to GLP-1 medications for weight management []
Amgens MariTide leads the GLP-1 obesity therapy market in 2025 with innovative design, Phase-3 trials, and strong potential for effective weight loss.
Euglycemic DKA
